A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

To be part of this study, you would need to have been diagnosed with ulcerative colitis for at least three months. Your UC should be causing moderate to severe symptoms, meaning it's quite active despite your current treatments. Importantly, your past or current treatments for UC, whether standard or advanced ones, should not have worked well enough for you, or you might have had a bad reaction to them.

There are also some reasons why you might not be able to join. For example, if you've had a large part of your colon removed, or if you're planning to have surgery for your UC. You also can't participate if you've been diagnosed with Crohn's disease or a similar condition, or if you've had certain advanced treatments for UC that target specific proteins (TL1a, IL-12, or IL-23) and they didn't work for you.

If you join this study, it would involve several stages. First, there's a 'screening' period that could last up to 5 weeks. During this time, doctors will check to make sure the study is right for you. After that, you'll enter the main 'induction phase' which lasts for 12 weeks. In this phase, you'll either receive the new study drug, RO7837195, or a dummy treatment (a 'placebo'). You won't know which one you're getting.

After these 12 weeks, everyone in the study will then receive the active study drug for about 40 weeks, regardless of what treatment you had initially. Throughout these phases, you'll have regular visits to the clinic for check-ups, assessments, and to make sure everything is going well. After your last dose of the study drug, there will be a follow-up period to monitor your health and any long-term effects. The total length of your involvement in the study will vary, but it includes these different treatment and follow-up phases.